Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review
Internal Medicine Journal · 2026
DOI: 10.1111/imj.70233 ↗Kurz gefasst
Fallbericht in der Zeitschrift Internal Medicine Journal, 2026. Verfasst von Sergio De Santos Belinchón und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Schnitzler Syndrome, Interleukin 1 Receptor Antagonist Protein, Antibodies, Monoclonal. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Schnitzler syndrome is a rare autoinflammatory syndrome caused by a dysregulation of the interleukin‐1β signalling pathway. Symptoms tend to appear in middle age and include urticariform skin lesions, fever, bone pain, lymphadenopathy and IgM monoclonal gammopathy. Interleukin‐1 (IL‐1) targeted therapy constitutes the basis for treatment and can lead to complete resolution of symptoms. We report a case of Schnitzler syndrome in a 49‐year‐old man refractory to anakinra and subsequently treated successfully with canakinumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Gregorio Marañón Institute of Health Research, Madrid, Spain.
- Department of Emergency, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Department of Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
ORCID-Profile: Sergio De Santos Belinchón, Pablo Daniel Lorenzo Barcia, Cristina Lavilla Olleros
Zitieren
APA
De Santos Belinchón, S., Ausín García, C., Lorenzo Barcia, P. D., Pire García, T., Balastegui Martín, H., Muñoz Delgado, C., Villalba García, M. V., & Lavilla Olleros, C. (2026). Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review. Internal Medicine Journal. https://doi.org/10.1111/imj.70233
Vancouver
De Santos Belinchón S, Ausín García C, Lorenzo Barcia PD, Pire García T, Balastegui Martín H, Muñoz Delgado C, et al. Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review. Internal Medicine Journal. 2026. doi:10.1111/imj.70233
BibTeX
@article{DeSantosBelinchn2026,
author = {De Santos Belinchón, Sergio and Ausín García, Cristina and Lorenzo Barcia, Pablo Daniel and Pire García, Tatiana and Balastegui Martín, Héctor and Muñoz Delgado, Cecilia and Villalba García, Maria Victoria and Lavilla Olleros, Cristina},
title = {Canakinumab as effective therapy in anakinra‐refractory Schnitzler syndrome: a case‐based review},
journal = {Internal Medicine Journal},
year = {2026},
doi = {10.1111/imj.70233}
}
EUVIMED